| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 72.46 | 42.2% | 199.2% |
| Total Income | 72.46 | 42.2% | 199.2% |
| Expenditure | 72.35 | 1.6% | 10.2% |
| PBT | -8.72 | 69.2% | 82.2% |
| Net Profit | -14.35 | 39.1% | 71.3% |
| OPM | 0.15% | 39.92pp | |
| NPM | -19.81% | 26.45pp | |
| EPS | -0.28 | 40.4% | 73.3% |
UroGen Pharma Reports Q2 2026 Results with $50.4M ZUSDURI Revenue
05 Aug 2026 · 5 Aug, 5:37 pm
Summary
UroGen Pharma Ltd. announced its financial results for the second quarter ended June 30, 2026, reporting total revenue of $72.5 million, a substantial increase from $24.2 million in the prior year's second quarter, driven by the commercial launch of ZUSDURI. ZUSDURI achieved $50.4 million in revenue, marking a 73% quarter-over-quarter growth. The company also highlighted progress in its pipeline, with UGN-103 on track for an NDA submission in Q3 2026 and UGN-501 slated for a Phase 1 trial initiation in Q4 2026. Management expressed confidence in establishing ZUSDURI as a foundational therapy and strengthening the long-term sustainability of the franchise through patent protection extending into 2044.
Key Highlights
- 1
ZUSDURI generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth.
- 2
Total revenue was $72.5 million in the second quarter ended June 30, 2026, a significant increase compared to $24.2 million in the second quarter of 2025.
- 3
The company expects a new U.S. patent, once issued, to provide protection into July 2044 for ZUSDURI and UGN-103.
- 4
UGN-103 is on track for an NDA submission in the third quarter of 2026, with potential FDA approval in 2027.
- 5
UGN-501 is expected to begin a Phase 1 trial in the fourth quarter of 2026.
- 6
JELMYTO generated net product revenue of $22.0 million in Q2 2026, and the company remains on track to deliver within its full-year guidance range of $97 million to $101 million.
- 7
UroGen reported a net loss of $14.4 million, or $0.28 per share, in Q2 2026, an improvement from a net loss of $49.9 million, or ($1.05) per share, in Q2 2025.
Management Comments
Liz Barrett
The second quarter marked another important step in establishing ZUSDURI as a foundational therapy for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The continued increase in utilization, expanding adoption across community practices, and growing repeat use reinforce our confidence we are building a durable commercial franchise with blockbuster potential. During the quarter, we strengthened the long-term sustainability of the franchise through a new U.S. patent allowance that, once the patent is issued, is expected to provide intellectual property coverage for both ZUSDURI and UGN-103 into July 2044. We believe this meaningfully enhances the long-term commercial opportunity for both products and further reinforces the sustainability of the franchise. Combined with the life-cycle expansion of UGN-103 and initiation of clinical development for UGN-501, we believe we are exceptionally well positioned to build a durable growth company and create long-term shareholder value.
Informational and educational content only. Not investment advice.